
Heron: Near The Bottom Of A Trading Range Despite Positives
HRTX • NASDAQ
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold HRTX in your mock portfolio yet.
Heron Therapeutics remains unprofitable, as indicated by its negative EPS and PE ratio. The lack of positive earnings suggests that the company is still in a cash-burning, development-heavy phase without clear profitability in the near term. This materially increases execution and financing risk for equity holders.
The stock has declined 21.5% over the last month and trades well below its 200-day moving average, signaling a weak intermediate-term trend. An RSI of 29.30 places the stock in oversold territory, suggesting potential for short-term technical bounces but within a broader downtrend. Overall, price action and trend indicators skew negative despite the possibility of near-term mean reversion.
Alternative data for Heron Therapeutics is mixed but modest in scale. Web traffic remains low, and job postings have declined, hinting at cautious hiring or cost control. However, LinkedIn follower growth shows a small but positive trend in professional interest or brand visibility.
Heron Therapeutics currently presents a high-risk profile, with persistent unprofitability and a sharply negative recent stock trend. While the oversold RSI could support short-term trading bounces and social media interest is inching higher, these positives are outweighed by weak earnings, a depressed price below the 200-day moving average, and soft alternative data. Overall, the balance of evidence points to a bearish stance until there is clearer progress on profitability and commercial traction.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: